Tempus

Executive Summary

Tempus is a Chicago-based technology company that leverages artificial intelligence to advance precision medicine. Founded in 2015, Tempus has built one of the world’s largest libraries of clinical and molecular data, coupled with an AI-powered operating system that makes this data actionable for healthcare providers, researchers, and patients. Initially focused on oncology, the company is expanding into neurology, psychiatry, cardiology, and radiology, positioning itself as a key player in the data-driven healthcare revolution. By integrating vast datasets with machine learning, Tempus aims to personalize treatment decisions, improve patient outcomes, and accelerate medical research. The company is privately held and has not disclosed its valuation or total funding, but its platform has the potential to disrupt traditional diagnostic and treatment paradigms. Tempus’s AI platform addresses a critical bottleneck in precision medicine: the ability to analyze and derive insights from complex multimodal data. Its operating system aggregates data from electronic health records, genomic sequencing, and imaging, then applies AI to identify patterns and recommend therapies. This approach has already shown promise in oncology, where Tempus partners with academic medical centers and biopharma companies to support clinical trials and drug development. Expansion into neurology and cardiology opens new avenues for growth, as these fields also suffer from data fragmentation. However, Tempus faces competition from other health AI companies and must navigate regulatory and data privacy challenges. Despite these risks, its comprehensive data asset and AI capabilities give it a strong moat. The conviction score reflects its leadership in a high-growth sector, offset by the lack of public financial disclosures.

Upcoming Catalysts (preview)

• Q3 2026Expansion of AI Platform into Neurology with Key Partnership60% success
• Q4 2026FDA Clearance for AI-Powered Diagnostic Tool in Oncology50% success
• Q2 2026Major Funding Round or Strategic Investment from Pharma70% success